The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity building, the initiative is the largest access-to-medicine program within Novartis measured by the number of patients reached annually. Together with our partners, and with our continued patient-centric approach, we are committed to the common goal of malaria elimination.

Content from this campaign

Health & Healthcare
Novartis Renews Commitment to Malaria Elimination, Investing USD 100 Million to Research and Develop Next-generation Antimalarials
Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting. Further, the company releases new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program.
Health & Healthcare
Novartis and Medicines for Malaria Venture Launch Patient Trial in Africa for KAF156, a Novel Compound Against Multidrug-resistant Malaria
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite.
Health & Healthcare
Malaria Fighter Rides Bicycle into Battle with Disease, Story from Novartis
Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority

Dismus Mwalukwanda works on the front line of the battle against malaria, one of the world’s deadliest diseases. He’s a community healthcare worker responsible for testing and treating patients in a remote part of rural Zambia, as well as teaching people how to combat the illness.
Health & Healthcare
Novartis Story About the Rising Concern of Malaria That Resists Treatment
In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old.
Health & Healthcare
Novartis Story Celebrates a Life Dedicated to Fighting Malaria
In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old.
Health & Healthcare
Lessons from Malaria Can Help Fight Against Antimicrobial Resistance
Two weeks ago, G20 leaders committed to working together to address one of the world’s most pressing and perplexing security threats: antimicrobial resistance (AMR) – a fierce and evolving adversary against which conventional therapeutic weapons are of no use.
Philanthropy
Partnering to Counter the Threat of Drug-resistant Malaria
Events
Watch: Together We Can End Malaria for Good - New Videos from Novartis Mark World Malaria Day
The fight against malaria continues to advance, led by the hard work of countless people. On World Malaria Day, meet some of the faces behind the Novartis Malaria Initiative and listen to their stories.
Philanthropy
The Specter of Malaria That Resists Treatment, New Photo Essay from Novartis
The fight against malaria continues to advance, led by the hard work of countless people who head out every day to their communities with a firm belief that they can make a difference. On World Malaria Day, a new photo essay from Novartis presents a collection of scenes on the ground.
AI & Technology
Novartis Launches SMS for Life 2.0 in Nigeria to Help Improve Access to Essential Medicines
Novartis announced today the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology. SMS for Life 2.0 is a joint public-private partnership led by Novartis and supported by its partners, the Kaduna State Ministry of Health and Vodacom.

More from Novartis

The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...